Continuous microfluidic mechano-poration of EVs for versatile cargo loading

XOMEXBIO — ENABLING EXOSOME ENRICHMENT

In addition to their natural immunomodulatory and anti-inflammatory activity, exosomes can provide a new method for targeted drug delivery. A robust and scalable method to enrich the vesicles with (water-soluble) molecules of interest, without altering their inherent properties, is invaluable to a bright future for therapeutic exosomes.

XomeXBio – a recently founded joint venture between ConvEyXO and our Chinese partner Somestech – is developing a unique microfluidic-chip-based solution. It allows precise and efficient loading, based on making the exosomes porous by squeezing them through the chip’s narrow channels.

XOMEXBIO — UNIQUE BENEFITS

PRECISE LOADING

All exosomes in the solution eventually pass through the chip’s nano-channels, with a maximum of one or two per channel at a time.

HIGH EFFICIENCY

The efficiency is around 10-fold higher compared to passive loading. The chips can be engineered to further increase loading efficiency with additional manipulations.

SIMPLE AUTOMATION

The microfluidic format is inherently highly compatible with a continuous process format and automation, which will positively impact product quality.

VERSATILE CARGO TYPES

Different drug substances can be loaded using the platform. The process has been validated with RNA, proteins, and water-soluble therapeutic compounds.

VERSATILE EXOSOME SOURCES

In addition to exosomes secreted by human stem cells, the platform can also enrich those derived from other sources like plant cells or bacteria. These present a more affordable alternative capable of the targeted delivery of the cargo, but without the inherent therapeutic properties of exosomes derived from stem cells.

A SCALABLE SOLUTION

The platform consists of two products:

  • A single chip capable of the small-scale production of GLP-grade material. This chip makes it possible to rapidly test the loading of different drug candidates, producing sufficient material for preclinical characterization.
  • An integrated scalable device for the automated large-scale production of GMP-grade therapeutic exosomes. This device will enable the production of sufficient quantities needed for clinical studies and beyond.

Would you like to learn more about our platform, or are you interested in collaborating? Get in touch!